Development of Entecavir: Superior Therapy for the Management of Chronic Hepatitis B Viral Infection

  • Deborah DeHertogh
  • Richard Colonno
  • William Fiske
  • Anne Cross
Conference paper


Current therapies for chronic hepatitis B virus (HBV) infection are limited by factors such as poor tolerability and viral resistance. The novel and selective HBV antiviral entecavir (Bristol-Myers Squibb Company; Wallingford, CT) has demonstrated potent activity against HBV and is in phase III clinical development. Oral entecavir has high bioavailability, shows linear pharmacokinetic properties in several ethnic populations, and is well tolerated. At doses of 0.5 mg to 1.0 mg daily, entecavir has significantly greater antiviral activity in nucleoside-naïve patients, assessed by reduction in HBV viral load, than the currently available therapy lamivudine. Entecavir also shows superior efficacy compared with lamivudine in reducing viremia and normalizing alanine aminotransferase levels in lamivudine-resistant patients. In addition, entecavir has demonstrated utility in the setting of HBV reinfection occurring in liver transplant recipients. Based on results of phase I and II dose-ranging, safety, and efficacy trials, several multinational phase III trials are currently ongoing. These studies are evaluating the optimal duration of therapy with entecavir, as well as the durability of response to this novel treatment for chronic HBV infection.


Lamivudine Therapy Woodchuck Hepatitis Virus Entecavir Treatment Entecavir Therapy Oral Entecavir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733–1745.PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization/OMS. Hepatitis B. Fact sheet. Infect Dis 2000.Google Scholar
  3. 3.
    Krogsgaard K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, Carreno V, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1994;21:646–655.PubMedCrossRefGoogle Scholar
  4. 4.
    Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312–323.PubMedGoogle Scholar
  5. 5.
    Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Feuery J, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258–1263.PubMedCrossRefGoogle Scholar
  6. 6.
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256–1263.PubMedCrossRefGoogle Scholar
  7. 7.
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in 72 HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714–717.PubMedGoogle Scholar
  8. 8.
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:16701677.Google Scholar
  9. 9.
    Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998;177:1382–1385.PubMedCrossRefGoogle Scholar
  10. 10.
    Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635–639.PubMedCrossRefGoogle Scholar
  11. 11.
    Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444–1448.PubMedGoogle Scholar
  12. 12.
    Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200–3208.PubMedGoogle Scholar
  13. 13.
    Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190–193.PubMedGoogle Scholar
  14. 14.
    Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002;46:2525–2532.PubMedCrossRefGoogle Scholar
  15. 15.
    Marion PL, Salazar FH, Winters MA, Colonno R. Potent efficacy of entecavir (BMS200475) in duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002;46:82–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Genovesi EV, Lamb L, Medina Taylor D, Seifer M, Innaimo S, Colonno RJ, et al. Efficacy of the carbocyclic 2’-deoxyguanosine nucleoside BMS-2 I,00475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998;42:3209–3217.PubMedGoogle Scholar
  17. 17.
    Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, Corey L, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236–1245.PubMedCrossRefGoogle Scholar
  18. 18.
    Yan J-H, Bifano M, Nichola P, O’Mara E, Loizillion E, Zhang D, Olsen S. Entecavir pharmacokinetics after multiple doses in healthy subjects. Presented at the 31st Annual Meeting of the American College of Clinical Pharmacology. September 21–23, 2002, San Francisco, CA.Google Scholar
  19. 19.
    de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, Gadano A, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578–582.PubMedCrossRefGoogle Scholar
  20. 20.
    Lai CL, Rosmawati M, Lao J, Van Vuerberghe H, Anderson FH, Thomas N, DeHertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831–1838.PubMedCrossRefGoogle Scholar
  21. 21.
    Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, et al. 73 The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449–455.PubMedCrossRefGoogle Scholar
  22. 22.
    Chang TT, Hadziyannis S, Cianciara J, Rizzeto M, Schiff E, Pastore G, Kleescaewski K, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology 2002; 36:300A. Abstract 550.Google Scholar
  23. 23.
    Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000;32:11891195.Google Scholar
  24. 24.
    Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, Brechot C, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813–815.PubMedCrossRefGoogle Scholar
  25. 25.
    Shakil AO, Lilly L, Angus P, Gerken G, Thomas N, Jean M, Joshi J. Entecavir significantly reduces viral load in liver transplant recipients failing lamivudine therapy for chronic hepatitis B infection [Abstract 585] presented at the 37th EASL Meeting, April 2002, Madrid. J Hepatol 2002;36:122.CrossRefGoogle Scholar

Copyright information

© Springer Japan 2004

Authors and Affiliations

  • Deborah DeHertogh
    • 1
  • Richard Colonno
    • 1
  • William Fiske
    • 2
  • Anne Cross
    • 1
  1. 1.Pharmaceutical Research Institute and Worldwide Medicine GroupBristol-Myers Squibb CompanyWallingford
  2. 2.Pharmaceutical Research Institute and Worldwide Medicine GroupBristol-Myers Squibb CompanyPrincetonUSA

Personalised recommendations